Cellmid logo

CDY - Cellmid Share Price

A$0.195 0.0  0.0%

Last Trade - 18/10/19

Sector
Healthcare
Size
Micro Cap
Market Cap £8.68m
Enterprise Value £6.41m
Revenue £3.25m
Position in Universe 1259th / 1833
Bullish
Bearish
Unlock CDY Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CDY Revenue Unlock CDY Revenue

Net Income

CDY Net Income Unlock CDY Revenue

Normalised EPS

CDY Normalised EPS Unlock CDY Revenue

PE Ratio Range

CDY PE Ratio Range Unlock CDY Revenue

Dividend Yield Range

CDY Dividend Yield Range Unlock CDY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CDY EPS Forecasts Unlock CDY Revenue
Profile Summary

Cellmid Limited develops and markets therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The Company operates in two segments: research and development of diagnostics and therapeutics, and research, development and marketing of hair growth products. It develops and commercializes diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine (Midkine Businesses, Lyramid and Kinera), and the development and sale of over-the-counter (OTC) treatments to alleviate excessive and abnormal hair loss, and re-establish the natural hair growth cycle (Consumer Health Business). Its products include Midkine ELISA kit; Advangen International hair loss products, and Evolis products, which are a range of hair growth products. The Company, through its subsidiaries, develops and sells treatments for various forms of hair loss (alopecia).

Directors
Last Annual June 30th, 2018
Last Interim December 31st, 2018
Incorporated October 8, 2004
Public Since December 9, 2005
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 84,108,592
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CDY Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CDY
Upcoming Events for CDY
Similar to CDY
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.